Hanna Squire, Jiun Youn, Bart A. Ellenbroek et al.
preprint
(±) 3,4-methylenedioxymethamphetamine (MDMA) is a recreationally abused psychostimulant that impairs memory performance. This effect is often attributed to a working memory impairment resulting from compromised serotonin systems. However, recent evidence from non-human animal experimental studies suggests that acute MDMA may indirectly impair memory performance through overstimulation of...
Lena K L Oestreich, Hugh McGovern, Zohaib Nadeem et al.
preprint
Background: The therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin has gained interest due to their potential efficacy in treating mental illness. We systematically reviewed the efficacy of MDMA and psilocybin in treating mental illness and explored the moderating effects of dosage, psychotherapeutic support, and concurrent antidepressant use. Methods: In this systematic...
Deborah Edwards, Judit Csontos, Michael J Pascoe et al.
preprint
Abstract Background: Adverse drug reactions (ADRs) can occur due to ecstasy use, and the number of people dying due to drug-related deaths has increased in the past 10 years. Harm reduction strategies could help prevent ADRs or decrease the incidence of life-threatening health consequences due to ecstasy use. However, no reviews have explored the breadth of evidence available on ecstasy harm...
Connor J Haggarty, Anya K. Bershad, Mahesh K Kumar et al.
3,4-methylenedioxymethamphetamine (MDMA) has long been used non-medically, and it is currently under investigation for its potential therapeutic benefits. Both uses may be related to its ability to enhance empathy, sociability, emotional processing and its anxiolytic effects. However, the neural mechanisms underlying these effects, and their specificity to MDMA compared to other stimulants, are...
bioRxiv (Cold Spring Harbor Laboratory)
Matthew J. Baggott, Kathleen J. Garrison
1 citation
preprint
Abstract Hyponatremia is a serious complication of 3,4-methylenedioxymethamphetamine (MDMA) use. We investigated potential mechanisms in two double-blind, placebo-controlled studies. In study 1, healthy drug-experienced volunteers received MDMA or placebo alone and in combination with the alpha-1 adrenergic inverse agonist prazosin, used as a positive control to release antidiuretic hormone...
Preprints.org
Kainat Riaz, Sejal Suneel, Mohammad Hamza Bin Abdul Malik et al.
1 citation
preprint
Post-traumatic stress disorder (PTSD) is a debilitating mental health disorder that causes significant dysfunction in individuals. Currently, there are many approved Pharmacotherapy and Psychotherapy treatment options for PTSD, but unfortunately, half of the patients do not respond to traditional therapies. In this article, we reviewed clinical trials and research on...
medRxiv
Warwick M. Green, Sanket B Raut, F.l.j. James et al.
4 citations
preprint
Abstract Post-Traumatic Stress Disorder (PTSD) causes broad impairments affecting quality of life. However, despite current treatment many people with PTSD do not fully recover. MDMA assisted psychotherapy has emerged as a new therapy for PTSD and its comorbidities. We aimed to analyse the current evidence for MDMA assisted psychotherapy in PTSD and associated quality of life, and physiological...
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al.
preprint
Background: After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names “molly” and “ecstasy,” has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). Areas of uncertainty: There is extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models...
Jason B. Luoma, M. Kati Lear, Kyong Yi et al.
preprint
This case report describes the application of in vivo and imaginal exposure techniqueswithin MDMA-assisted therapy (MDMA-AT) for social anxiety disorder (SAD). The treatment,conducted as part of a randomized controlled trial, consisted of three non-drug preparationsessions, two drug sessions, and six non-drug integration sessions. Exposure interventionsincluded imaginal exposure to...
Philip Gerrans, Hugh Mgovern, Jakob Hohwy et al.
1 citation
preprint
Complex post-traumatic stress disorder (C-PTSD) is a newly recognized diagnosis that is distinguished from post-traumatic stress disorder (PTSD) through additional symptom clusters beyond re-experiencing, avoidance, and a persistent sense of threat. In addition to these core PTSD symptoms, C-PTSD is characterized by disturbances in self-organization, including affective dysregulation, negative...